Katharine Knobil joins Pliant Therapeutics’ Board of Directors

Pliant Therapeutics has appointed Katharine Knobil to its Board of Directors.
Speaking of Katharine’s appointment, Bernard Coulie, MD, PhD, President and CEO of Pliant stated: “I would like to extend a warm welcome to Kate, whose global clinical development and strategic leadership experience, including her training as a pulmonologist, aligns perfectly with Pliant as we evolve into a late-stage biotechnology company. I look forward to working with Kate, and believe she will provide valuable perspectives as we continue to execute on our strategy of making a difference in the lives of patients impacted by fibrotic diseases.”
Pliant Therapeutics is a clinical stage biopharmaceutical company which focuses on discovering and developing novel therapies for fibrosis. In addition to clinical stage programmes, Pliant currently has two preclinical programmes targeting oncology and muscular dystrophies.
Dr Katharine Knobil is an accomplished pharmaceutical executive who brings over 20 years of clinical development and medical affairs expertise.